A PET study in healthy subjects of brain exposure of (11)C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer

Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor regions are important criteria for evaluation and confirmation of CNS efficacy. The aim of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cereb Blood Flow Metab
Autors principals: Varrone, Andrea, Varnäs, Katarina, Jucaite, Aurelija, Cselényi, Zsolt, Johnström, Peter, Schou, Magnus, Vazquez-Romero, Ana, Moein, Mohammad M, Halldin, Christer, Brown, Andrew P, Vishwanathan, Karthick, Farde, Lars
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7168784/
https://ncbi.nlm.nih.gov/pubmed/31006308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0271678X19843776
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars